Related Experiment Video
Updated: Jun 1, 2026
04:38
A Novel Technique of Rescuing Capsulorhexis Radial Tear-out using a Cystotome
Published on: January 16, 2011
[CAPS treatment]
Santiago Jiménez Treviño1, Eduardo Ramos Polo
1Departamento de Pediatría, Hospital Universitario Central de Asturias, Oviedo, España. principevegeta@hotmail.com
Medicina Clinica
|May 21, 2011
Summary
New biologic therapies targeting interleukin-1 (IL-1) show promise for cryopyrin-associated periodic syndromes (CAPS). These treatments improve symptoms and control inflammation, offering hope for patients with this rare genetic disorder.
Area of Science:
- Immunology
- Genetics
- Rheumatology
Background:
- Cryopyrin-associated periodic syndromes (CAPS) are rare genetic inflammatory diseases.
- Traditional treatments like NSAIDs and corticoids offer limited efficacy for CAPS.
- Understanding CAPS pathogenesis involves inflammasome activation and interleukin-1 (IL-1) overproduction.
Purpose of the Study:
- To evaluate the efficacy of novel IL-1 targeting therapies for CAPS.
- To assess the impact of these therapies on clinical symptoms and inflammatory markers.
- To explore the potential of IL-1 blockade in preventing long-term complications of CAPS.
Main Methods:
- Review of studies on anakinra, rilonacept, and canakinumab in CAPS patients.
- Analysis of clinical outcomes, including symptom improvement and quality of life.
- Monitoring of inflammatory markers to assess treatment response.
Main Results:
- Anakinra, an IL-1 receptor antagonist, demonstrated significant improvement in clinical symptoms and inflammatory markers in CAPS patients.
- Further research has led to the development and investigation of other IL-1 targeting agents like rilonacept and canakinumab.
- These targeted therapies effectively manage the underlying inflammation in CAPS.
Conclusions:
- Targeted inhibition of IL-1 represents a breakthrough in managing CAPS.
- Biologic therapies offer substantial benefits for patients, improving both symptoms and quality of life.
- IL-1 blockade holds potential for preventing chronic inflammatory complications associated with CAPS.
Related Concept Videos
01:28Endoscopic Procedures III: Video Capsule Endoscopy
Capsule endoscopy, or wireless or video capsule endoscopy, is a diagnostic procedure for examining the entire gastrointestinal tract. Patients swallow a capsule about the size of a vitamin tablet. The capsule is equipped with a transmitter, a battery, an LED light source, and a color video camera to capture images throughout the gastrointestinal tract. This procedure is particularly useful for diagnosing conditions such as Crohn's disease, ulcerative colitis, tumors, polyps, ulcers, unexplained...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:24Treatment Strategies for Psychological Disorders
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...